<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13432">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100007</url>
  </required_header>
  <id_info>
    <org_study_id>ME-344-002</org_study_id>
    <nct_id>NCT02100007</nct_id>
  </id_info>
  <brief_title>ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors</brief_title>
  <official_title>A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEI Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MEI Pharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of ME-344 when given
      in combination with Hycamtin® in patients with solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Combination of dosing ME-344 in combination with topotecan in patients with solid tumors</measure>
    <time_frame>One 28 day cycle</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be administered ME-344 10 mg/kg IV infusions in combination with topotecan 4 mg/m2 i.v. If dose-limiting toxicity is observed an additional patients may be treated with ME-344 at the 5 mg/kg dose level. Patients will be assessed by physical exam, vital signs, changes in ECOG status, hematology labs, clinical chemistry labs, urinalysis, and ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetic profile of ME-344 in combination with topotecan</measure>
    <time_frame>Cycle 1 Day 1, at 0, .5, 1, 2, 4, 6 and 24 hours post-dose and Day 15 at 0 and end of infusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Peak Plasma Concentration (Cmax) and Area under the plasma concentration  versus time curve (AUC) of ME-344 in combination with topotecan</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ME-344</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ME-344</intervention_name>
    <description>Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.
Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator.</description>
    <arm_group_label>ME-344</arm_group_label>
    <other_name>open label</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.</description>
    <arm_group_label>ME-344</arm_group_label>
    <other_name>Hycamtin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic confirmed locally advanced or metastatic small cell lung
             cancer, ovarian cancer, or cervical cancer (Part 1); small cell lung cancer and
             ovarian cancer (Part 2)

          -  Patients with ovarian and small cell lung cancer must have failed initial therapy

          -  Patients with carcinoma of the cervix must have advanced disease not amenable to
             curative surgery and/or radiation therapy

          -  Patients may not have received more than 4 prior regimens of therapy

          -  Patients may not previously have received irinotecan, topotecan or other
             topoisomerase I inhibitor

          -  ECOG Performance status 0-1 (Appendix B)

          -  A minimum life expectancy of 12 weeks

          -  Adequate bone marrow, hepatic and renal function as evidenced by:

               -  Absolute neutrophil count (ANC) &gt; 1.5 x 109/L

               -  Platelet count &gt; 100 x 109/L

               -  Hemoglobin &gt; 9.0 g/dL

               -  Serum bilirubin &lt; 1.5 x ULN

               -  AST/ALT (SGOT/SGPT) &lt; 2.5 x ULN for the reference laboratory or &lt; 5 x --ULN in
                  the presence of liver metastases

               -  Serum creatinine &lt; 1.5 x ULN or creatinine clearance ≥ 60 mL/min as measured by
                  institutional standards

          -  At least 21 days must have elapsed prior to Day 1 Cycle 1, since any radiotherapy,
             immunotherapy or following major surgery; any surgical incision should be completely
             healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 since &quot;limited
             palliative radiotherapy&quot;, defined as a course of therapy encompassing &lt;25% total bone
             marrow volume and not exceeding 30 GY.

        Exclusion Criteria:

          -  Patients with tumor involvement of the Central Nervous System (CNS).  SCLC patients
             with previously treated CNS lesions must have stable CNS disease for at least 4 weeks

          -  Patients with uncontrolled infection or systemic disease

          -  Patients with clinically significant cardiac disease not well controlled with
             medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g.
             angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months

          -  Patients who have toxicity from last prior therapy that has not recovered to at least
             Grade 1, with the exception of Grade 2 alopecia

          -  Patients who have had any chemotherapy regimens, biologic, or targeted therapies
             within the 2 weeks prior to Cycle 1 Day 1

          -  Patients with any neuropathy &gt; Grade 1

          -  Patients with known hypersensitivity to any components of ME-344 or topotecan study
             drug product

          -  Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active,
             previously treated or both)

          -  Patients with a history of solid organ transplantation

          -  Patients with any psychiatric disorder or social or geographic situation that would
             preclude  study participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy J Levin, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>MEI Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Esquibel</last_name>
    <phone>858-369-7174</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Oncology Hematology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mericle, RN</last_name>
      <phone>480-860-5000</phone>
      <email>dmericle@azoph.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Chiles</last_name>
      <phone>720-848-5097</phone>
      <email>haley.chiles@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Diamond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Hoyer</last_name>
      <phone>312-695-1341</phone>
      <email>amy.hoyer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Sanmann</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48633</phone_ext>
      <email>amy-sanmann@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Katheleen Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Brisendine</last_name>
      <phone>843-792-9007</phone>
      <email>brisend@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Britten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marla Schider, RN</last_name>
      <phone>615-339-4214</phone>
      <email>ASKSARAH@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of WA Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey Mesher</last_name>
      <phone>206-288-2056</phone>
      <email>mollerup@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Goff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.meipharma.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>relapsed</keyword>
  <keyword>advanced</keyword>
  <keyword>metastatic</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>refractory</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
